153 related articles for article (PubMed ID: 38676720)
1. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification.
Tropeano MP; Raspagliesi L; Bono BC; Baram A; Rossini Z; Franzini A; Navarria P; Clerici E; Bellu L; Simonelli M; Scorsetti M; Riva M; Politi LS; Pessina F
Acta Neurochir (Wien); 2024 Apr; 166(1):196. PubMed ID: 38676720
[TBL] [Abstract][Full Text] [Related]
2. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
3. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
Neuro Oncol; 2023 Sep; 25(9):1672-1685. PubMed ID: 37253096
[TBL] [Abstract][Full Text] [Related]
4. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.
Karschnia P; Young JS; Dono A; Häni L; Sciortino T; Bruno F; Juenger ST; Teske N; Morshed RA; Haddad AF; Zhang Y; Stoecklein S; Weller M; Vogelbaum MA; Beck J; Tandon N; Hervey-Jumper S; Molinaro AM; Rudà R; Bello L; Schnell O; Esquenazi Y; Ruge MI; Grau SJ; Berger MS; Chang SM; van den Bent M; Tonn JC
Neuro Oncol; 2023 May; 25(5):940-954. PubMed ID: 35961053
[TBL] [Abstract][Full Text] [Related]
5. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
7. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.
Karschnia P; Dietrich J; Bruno F; Dono A; Juenger ST; Teske N; Young JS; Sciortino T; Häni L; van den Bent M; Weller M; Vogelbaum MA; Morshed RA; Haddad AF; Molinaro AM; Tandon N; Beck J; Schnell O; Bello L; Hervey-Jumper S; Thon N; Grau SJ; Esquenazi Y; Rudà R; Chang SM; Berger MS; Cahill DP; Tonn JC
Neuro Oncol; 2024 Jan; 26(1):166-177. PubMed ID: 37665776
[TBL] [Abstract][Full Text] [Related]
8. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
Yan JL; van der Hoorn A; Larkin TJ; Boonzaier NR; Matys T; Price SJ
J Neurosurg; 2017 Jan; 126(1):234-241. PubMed ID: 27058207
[TBL] [Abstract][Full Text] [Related]
9. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
[TBL] [Abstract][Full Text] [Related]
10. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
12. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
[TBL] [Abstract][Full Text] [Related]
13. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Li YM; Suki D; Hess K; Sawaya R
J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
[TBL] [Abstract][Full Text] [Related]
14. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
15. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
16. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
17. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection.
Shah AH; Mahavadi A; Di L; Sanjurjo A; Eichberg DG; Borowy V; Figueroa J; Luther E; de la Fuente MI; Semonche A; Ivan ME; Komotar RJ
J Neurooncol; 2020 Jul; 148(3):501-508. PubMed ID: 32627128
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
